NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
Skip to content
Veracyte to Participate in the Cowen 42nd Annual Health Care Conference
<< Back
Mar 1, 2022

Veracyte to Participate in the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 1, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a presentation at Cowen’s 42nd Annual Health Care Conference on March 8th at 12:50 p.m. Eastern Time.

A live audio webcast of the company’s presentation will be available on Veracyte’s website at https://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the 10 most prevalent cancers by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to a best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Investors:
investors@veracyte.com
619-393-1545

Media:
Tracy Morris
Vice President of Corporate Communications & Investor Relations
tracy.morris@veracyte.com
650-380-4413

Source: Veracyte, Inc.